Semaphorin-3A protects against neointimal hyperplasia after vascular injury.

ABSTRACT:

Background

Neointimal hyperplasia is a prominent pathological event during in-stent restenosis. Phenotype switching of vascular smooth muscle cells (VSMCs) from a differentiated/contractile to a dedifferentiated/synthetic phenotype, accompanied by migration and proliferation of VSMCs play an important role in neointimal hyperplasia. However, the molecular mechanisms underlying phenotype switching of VSMCs have yet to be fully understood.

Methods

The mouse carotid artery ligation model was established to evaluate Sema3A expression and its role during neointimal hyperplasia in vivo. Bioinformatics analysis, chromatin immunoprecipitation (ChIP) assays and promoter-luciferase reporter assays were used to examine regulatory mechanism of Sema3A expression. SiRNA transfection and lentivirus infection were performed to regulate Sema3A expression. EdU assays, Wound-healing scratch experiments and Transwell migration assays were used to assess VSMC proliferation and migration.

Findings

In this study, we found that semaphorin-3A (Sema3A) was significantly downregulated in VSMCs during neointimal hyperplasia after vascular injury in mice and in human atherosclerotic plaques. Meanwhile, Sema3A was transcriptionally downregulated by PDGF-BB via p53 in VSMCs. Furthermore, we found that overexpression of Sema3A inhibited VSMC proliferation and migration, as well as increasing differentiated gene expression. Mechanistically, Sema3A increased the NRP1-plexin-A1 complex and decreased the NRP1-PDGFR? complex, thus inhibiting phosphorylation of PDGFR?. Moreover, we found that overexpression of Sema3A suppressed neointimal hyperplasia after vascular injury in vivo.

Interpretation

These results suggest that local delivery of Sema3A may act as a novel therapeutic option to prevent in-stent restenosis.

SUBMITTER: Wu JH 

PROVIDER: S-EPMC6355729 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature